Avitia provides an AI-driven next-generation sequencing platform and non-invasive liquid biopsy tests for cancer mutation identification. Its solutions help laboratories and clinicians conduct molecular testing locally, accelerate treatment decisions, and support clinical trial matching.
Avitia is a Medical & telehealth project. It focuses on identifying cancer mutations quickly and locally so clinicians can select targeted treatments and match patients to clinical trials. Avitia is a B2B product aimed at clinical laboratories, oncologists, and healthcare providers. Pricing is enterprise-only. It runs on the web.
It is developed by Avitia. Key capabilities include liquid biopsy testing, mutation identification, and next-generation sequencing. The interface is available in English and French.
Summary written by a language model from the project’s public pages.
What PulseGate has recorded for this listing
Same category — not a similarity match